When did Array BioPharma go public?
The company went public on Oct. 15 at an IPO price of $22 a share, and the stock closed as high as $51.05 on Jan. 22 before starting to sell off.
Is array Tech profitable?
Array Technologies is also expected to turn profitable, with statutory earnings of US$0.079 per share. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$1.07b and earnings per share (EPS) of US$0.66 in 2021.
Is Arry a good stock to buy?
Array Technologies has received a consensus rating of Buy. The company’s average rating score is 2.54, and is based on 7 buy ratings, 6 hold ratings, and no sell ratings.
What does Array BioPharma do?
Array BioPharma Inc. (NASDAQ: ARRY) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.
Who bought Array BioPharma?
Pfizer Inc.
Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Array BioPharma Inc., advancing breakthrough science for the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need.
Is Array Technologies a buy?
Investor Takeaway. Array Technologies has fallen hard since the earnings release, as management pulled guidance due to unforeseen rises in steel and shipping costs. Array is currently a Buy for investors who have a well-diversified portfolio and can accept near-term uncertainty.
Is array a SPAC?
Profitable solar tracker company Array Technologies is going public the old-fashioned way and eschewing the SPAC method being employed by other renewable companies such as QuantumScape and ChargePoint.
Will ARRY stock go up?
Will Array Technologies stock price grow / rise / go up? Yes. The ARRY stock price can go up from 13.450 USD to 19.244 USD in one year.
Who owns array technologies?
Ron P. Corio
Key Executives
| Name | Title | Exercised |
|---|---|---|
| Mr. James M. Fusaro | CEO & Director | N/A |
| Mr. Ron P. Corio | Founder & Director | N/A |
| Mr. Jeffrey P. Krantz | Chief Commercial Officer | N/A |
| Mr. Nipul A. Patel | Chief Financial Officer | N/A |
Who is the CEO of Array BioPharma Inc?
BOULDER, Colo. , March 5, 2019 /PRNewswire/ — Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the 39 th Annual Cowen Health Care Conference in Boston . The public is welcome to participate in the conference through a webcast on the
How much did Pfizer buy Array Biopharma for?
US drug giant Pfizer just announced that it is acquiring biotech Array BioPharma for $11.4 billion. This latest deal points to a trend of big companies snapping up cancer-focused biotechs, with Merck buying the cancer biotech Tilos Therapeutics for up to $773 million last week.
What is the market capitalization of Array BioPharma?
Array BioPharma’s current market capitalization is $10.7 b. BOULDER, Colo., July 30, 2019 /PRNewswire/ — Array BioPharma Inc. (“Array”) today announced that, in connection with the closing of the merger (the “Merger”) contemplated by the Agreement and Plan of Merger (the “Merger Agreement”), dated as of June 14, 2019, by and among Array, Pfizer…
